This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Simpson, D. J. Articles by Farrell, W. E. Search for Related Content PubMed PubMed Citation Articles by Simpson, D. J. Articles by Farrell, W. E.

Chromosome 13q Deletion Mapping in Pituitary Tumors

Infrequent Loss of the Retinoblastoma Susceptibility Gene (RB1) Locus Despite Loss of RB1 Protein Product in Somatotrophinomas¹

Centre for Cell and Molecular Medicine, School of Postgraduate Medicine, Keele University, North Staffordshire Hospital, Stoke-on Trent ST4 7QB, United Kingdom [D. J. S., J. M., J. E. B., R. N. C., W. E. F.]; Division of Endocrinology and Metabolism, University of Michigan Medical Centre, Ann Arbor, Michigan 48109 [A. L. B.]; and University Department of Pathology, Glasgow Royal Infirmary, Glasgow G4 OSF, United Kingdom [A. M. M., W. E. F.]

Two recent studies have described allelic loss of an RB1 intragenic marker on chromosome 13q in aggressive and metastatic pituitary tumors that did not correlate with loss of pRB. The second report also showed that losses were more frequently associated with a more centromeric marker. Because both of these studies suggest the presence of another or other tumor suppressor genes (TSGs) on 13q, we carried out an allelotype analysis encompassing known and recently described TSG loci on 13q, together with immunohistochemical analysis of pRB.

We analyzed 82 nonfunctional tumors and 53 somatotrophinomas subdivided into invasive and noninvasive cohorts. A significantly higher frequency of loss, at one or more of 13 markers, was evident in the invasive nonfunctional tumors (54%, 26 of 48) than in their noninvasive counterparts (29%, 10 of 34). An approximately equal frequency of loss was apparent in invasive (28%, 5 of 18) and noninvasive (31%, 11 of 35) somatotrophinomas at one or more markers. In those tumors harboring deletion, loss at two or more markers was more frequent in invasive nonfunctional tumors 65% (17 of 26) compared with 36% (4 of 11) of their noninvasive counterparts. In somatotrophinomas, 40% (2 of 5) of invasive tumors as compared with 64% (7 of 11) of noninvasive tumors had evidence of two or more deletions. In tumors showing loss at two or more loci, the majority showed large deletions; however, loss of the RB1 intragenic marker D13S153 was infrequent. In most cases, loss at individual markers was more frequent in invasive tumors than their noninvasive counterparts. A marker 3 cM telomeric to RB1 (D13S1319) showed the highest frequency of deletion in both invasive cohorts (29% of somatotrophinomas and 24% of nonfunctional tumors).

Immunohistochemical analysis of pRB showed frequent loss in somatotrophinomas (27%, 9 of 33) in comparison with 4% (2 of 53) of nonfunctional tumors. Although loss of pRB did not correlate with loss of an intragenic marker or tumor grade, it was significantly associated with the somatotrophinoma subtype (P = 0.002). These data suggest that chromosome 13q is a frequent target for allelic deletion in pituitary tumors and point to another or other TSG loci in these regions.

This article has been cited by other articles:

				M. A. Fernando and A. P. Heaney {alpha}1-Adrenergic Receptor Antagonists: Novel Therapy for Pituitary Adenomas Mol. Endocrinol., December 1, 2005; 19(12): 3085 - 3096. [Abstract] [Full Text] [PDF]

				A. Lania, G. Mantovani, and A. Spada Genetics of Pituitary Tumors: Focus on G-Protein Mutations Experimental Biology and Medicine, October 1, 2003; 228(9): 1004 - 1017. [Abstract] [Full Text] [PDF]

				D. J. Simpson, S. J. Frost, J. E. Bicknell, J. C. Broome, A. M. McNicol, R. N. Clayton, and W. E. Farrell Aberrant expression of G1/S regulators is a frequent event in sporadic pituitary adenomas Carcinogenesis, August 1, 2001; 22(8): 1149 - 1154. [Abstract] [Full Text] [PDF]

				R. N. Clayton, M. Pfeifer, A. B. Atkinson, P. Belchetz, J. A. H. Wass, E. Kyrodimou, M. Vanderpump, D. Simpson, J. Bicknell, and W. E. Farrell Different Patterns of Allelic Loss (Loss of Heterozygosity) in Recurrent Human Pituitary Tumors Provide Evidence for Multiclonal Origins Clin. Cancer Res., October 1, 2000; 6(10): 3973 - 3982. [Abstract] [Full Text]